Clinical trial
A Randomized, Double-blind, Multi-center, Therapeutic Confirmatory, Phase 3 Trial To Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy Versus D064 or D702 Monotherapy in Essential Hypertension Patients
NCT06121518 is registered in ClinicalTrials.gov with Chong Kun Dang Pharmaceutical as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Multi-center, Therapeutic Confirmatory, Phase 3 Trial To Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy Versus D064 or D702 Monotherapy in Essential Hypertension Patients
- Lead sponsor
- Chong Kun Dang Pharmaceutical
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- July 31, 2023
- Completion date
- March 26, 2024
- Enrollment
- 235 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.